Read the entire article at: www.bioworld.com/articles/699721-in-the-clinic-for-aug-8-2023

https://podcasts.apple.com/us/podcast/episode-37-david-bearss-ph-d-president-and-ceo-of/id1648796570?i=1000616814121 David Bearss, President and CEO of Halia Therapeutics, and Todd Kays, Vice President of Dermatology at Vile Health Technologies, discuss the connection...

Halia Therapeutics – Eliminating Chronic Inflammation by Targeting the NLRP3 Inflammasome Dr. David Bearss, PhD, President and CEO at Halia Therapeutics, a clinical-stage biopharma company developing novel therapies to improve the lives of patients with inflammatory...

We are proud to announce that Halia CEO David Bearss Ph.D. will be awarded the 2023 Governor’s Medal for Science and Technology on May 2nd at the One Utah Summit. https://business.utah.gov/news/recipients-of-the-2023-utah-governors-science-medals-announced/

The Bio Report David Bearss Ph.D., president and CEO of Halia Therapeutics, Inc., discusses with Daniel Levine the NLRP3 inflammasome, the role it plays in Alzheimer’s disease and other neurologic conditions, and the case for the company's therapeutic approach....

Empowered Patient Podcast David Bearss the Co-Founder, CEO and President of Halia Therapeutics, points out that despite traditional thinking, chronic inflammation is not just an unresolved acute inflammatory response. It has been discovered that a different pathway...

BioSpace Biopharma Execs Adopt Creative Mindset at BIO CEO https://www.biospace.com/article/biopharma-execs-adopt-creative-mindset-at-bio-ceo-/

STAT Up and down the ladder: The latest comings and goings https://www.statnews.com/pharmalot/2023/01/20/pharma-jobs-dianthus-catalent-cytovance/

Fierce Biotech Chutes & Ladders—David Kessler resigns from the Biden admin, marking the unofficial end of Operation Warp Speed https://www.fiercebiotech.com/biotech/chutes-ladders-david-kessler-resigns-biden-admin-marking-unofficial-end-operation-warp

Endpoints News 'Perfect time': SIGA's CEO on retirement; Juvenescence woos GSK vet to lead anti-aging play https://endpts.com/biopharma-jobs-report-perfect-time-sigas-ceo-on-retirement-juvenescence-woos-gsk-vet-to-lead-anti-aging-play/

The Pharma Letter Amgen’s Margit Janát-Amsbury named Halia CMO https://www.thepharmaletter.com/article/amgen-s-margit-janat-amsbury-named-halia-cmo

BioWorld Appointments and advancements for Jan. 19, 2023 https://www.bioworld.com/articles/693419-appointments-and-advancements-for-jan-19-2023?v=preview

CFO DIVE Biotech CFOs sharpen financing tactics for lean times https://www.cfodive.com/news/3-biotech-cfos-finding-financing-lean-times/640301/

David J. Bearss, Ph.D., Co-Founder, and CEO of Salt Lake City-based Halia Therapeutics, for his limitless and inspiring entrepreneurial spirit, mentorship, and achievements that are transforming therapeutics, spawning discovery, seeding startups, and strengthening...

by Jeremie Oliver May 20, 2022 For Utah Business, I’ve covered biotechnology breakthroughs ranging from breast cancer diagnosis to novel intestinal disease therapeutics. But we haven’t yet discussed a disease that is even more prevalent than those combined:...

Published: Dec 2, 2017, at 5:20 p.m. By Deseret News PROVO — A new way to examine Alzheimer's disease has provided a tantalizing potential treatment approach to prevent the devastating condition, according to BYU-led research published online in the journal Genome...